$2.34 0.1 4.9%
Last Trade - 04/03/21
| Market Cap | ÂŁ76.8m |
| Enterprise Value | ÂŁ56.1m |
| Revenue | ÂŁ8.65m |
| Position in Universe | 4988th / 6640 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 20.9 | 12.1 | 9.30 | 19.7 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 6, 2012 |
| Public Since | April 15, 2015 |
| No. of Shareholders: | 13 |
| No. of Employees: | 79 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 48,043,143 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 6310 Nancy Ridge Dr Ste 101, SAN DIEGO, 92121-3209, United States |
| Web | http://www.cidara.com/ |
| Phone | +1 858 7526170 |
| Contact | Robert Uhl (IR Contact Officer) |
| Auditors | Ernst & Young LLP |
As of 04/03/21, shares in Cidara Therapeutics Inc are trading at $2.34, giving the company a market capitalisation of ÂŁ76.8m. This share price information is delayed by 15 minutes.
Shares in Cidara Therapeutics Inc are currently trading at $2.34 and the price has moved by -22.03% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cidara Therapeutics Inc price has moved by -36.94% over the past year.
Of the analysts with advisory recommendations for Cidara Therapeutics Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cidara Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Cidara Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Cidara Therapeutics Inc does not currently pay a dividend.
Cidara Therapeutics Inc does not currently pay a dividend.
Cidara Therapeutics Inc does not currently pay a dividend.
To buy shares in Cidara Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Cidara Therapeutics Inc are currently trading at $2.34, giving the company a market capitalisation of ÂŁ76.8m.
Here are the trading details for Cidara Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Cidara Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Cidara Therapeutics Inc are currently priced at $2.34. At that level they are trading at 0.187% discount to the analyst consensus target price of 0.00.
Analysts covering Cidara Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.607 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cidara Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -37.67%. At the current price of $2.34, shares in Cidara Therapeutics Inc are trading at -25.79% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Cidara Therapeutics Inc.
Cidara Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Cidara Therapeutics Inc based on the size of their shareholding:
